Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Mitoxantrone-Based Novel Conditioning Regimen Leads to Great Survival Benefit in Peripheral T-Cell Lymphoma Compared to BEAM Regimen.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
- Publication Information:
Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
- Subject Terms:
- Abstract:
Background: Peripheral T-cell lymphomas (PTCL) frequently result in relapsed or refractory diseases. Upfront autologous hematopoietic stem cell transplantation (ASCT) using the BEAM (carmustine, etoposide, cytarabine, and melphalan) regimen is recommended. However, relapses are common in PTCL, highlighting a critical need for improved survival outcomes in these patients.
Objective: Anthracycline drugs are essential in treating PTCL. We compared the efficacy and tolerability of a high-dose mitoxantrone-based conditioning regimen [mitoxantrone, cyclophosphamide, and etoposide (MCE)] to the BEAM regimen in upfront ASCT for newly diagnosed PTCL patients who achieved complete or partial remission after induction therapy.
Study Design: A retrospective study was conducted to analyze the treatment response, progression-free survival (PFS), overall survival (OS), hematologic engraftment time, and adverse events of 64 patients between two regimens, who achieved complete or partial remission after induction chemotherapy. Twenty-eight patients received the MCE regimen, while 36 patients were treated with the BEAM regimen.
Results: There were no significant differences in clinical characteristics or the incidence of adverse events between the two groups. However, the median OS significantly favored the MCE group at 102.4 (95% CI, 87.0-117.8) months compared to 62.6 (95% CI, 50.8-74.5) months in the BEAM group (p = 0.023). Similarly, the median PFS was longer in the MCE group at 87.8 (95% CI, 65.8-109.8) months versus 42.5 (95% CI, 30.0-55.0) months in the BEAM group (p = 0.031).
Conclusion: ASCT with the mitoxantrone-based conditioning regimen is tolerable and appears to significantly improve the prognosis of PTCL patients, offering a promising alternative to the current standard of care.
(© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.)
- References:
Transplant Cell Ther. 2021 Jul;27(7):571-588. (PMID: 33857661)
Oncologist. 2018 Sep;23(9):1039-1053. (PMID: 29674443)
Biol Blood Marrow Transplant. 2015 Jun;21(6):1046-1053. (PMID: 25687795)
Front Oncol. 2019 Sep 10;9:892. (PMID: 31552193)
J Clin Oncol. 2007 Feb 10;25(5):579-86. (PMID: 17242396)
Curr Hematol Malig Rep. 2017 Jun;12(3):217-226. (PMID: 28478586)
Blood. 2021 May 13;137(19):2646-2656. (PMID: 33512419)
Br J Haematol. 2017 Mar;176(5):750-758. (PMID: 27983760)
Bone Marrow Transplant. 2019 Jun;54(6):877-884. (PMID: 30413811)
Bone Marrow Transplant. 2020 Apr;55(4):796-803. (PMID: 31695174)
J Clin Oncol. 1999 Apr;17(4):1244. (PMID: 10561185)
Transplant Proc. 2023 Jan-Feb;55(1):235-241. (PMID: 36639277)
Ann Hematol. 2023 Nov;102(11):3185-3193. (PMID: 37700194)
Bone Marrow Transplant. 2000 Feb;25(3):309-13. (PMID: 10673703)
Chin Med J (Engl). 2021 Jun 16;134(13):1584-1592. (PMID: 34133361)
Am J Hematol. 2024 Jun;99(6):1180-1183. (PMID: 38526002)
Transplant Cell Ther. 2024 Aug;30(8):774.e1-774.e12. (PMID: 38768908)
Bone Marrow Transplant. 2022 Oct;57(10):1612-1614. (PMID: 35879604)
Cancer Med. 2024 Jan;13(2):e6965. (PMID: 38348996)
J Hematol Oncol. 2020 May 19;13(1):56. (PMID: 32429979)
Bone Marrow Transplant. 2018 Dec;53(12):1553-1559. (PMID: 29884850)
Blood. 2011 Sep 22;118(12):3419-25. (PMID: 21816830)
J Clin Oncol. 2013 Jun 1;31(16):1970-6. (PMID: 23610113)
Front Immunol. 2023 Apr 04;14:1128172. (PMID: 37081867)
Sci Rep. 2022 Aug 23;12(1):14369. (PMID: 35999255)
Transfusion. 2024 May;64(5):871-880. (PMID: 38600674)
Bone Marrow Transplant. 2007 Sep;40(6):505-13. (PMID: 17589535)
- Grant Information:
21Y11909000 Science and Technology Commission of Shanghai Municipality; HD0103 the Elite Project of Huadong hospital; 202140518 Shanghai Municipal Health Commission
- Contributed Indexing:
Keywords: T‐cell lymphomas; autologous stem cell transplantation; carmustine; conditioning regimen; mitoxantrone
- Accession Number:
BZ114NVM5P (Mitoxantrone)
04079A1RDZ (Cytarabine)
Q41OR9510P (Melphalan)
6PLQ3CP4P3 (Etoposide)
U68WG3173Y (Carmustine)
8N3DW7272P (Cyclophosphamide)
- Publication Date:
Date Created: 20241209 Date Completed: 20241209 Latest Revision: 20241211
- Publication Date:
20241211
- Accession Number:
PMC11626477
- Accession Number:
10.1002/cam4.70476
- Accession Number:
39651710
No Comments.